Management of giant cell tumor of bone in the era of denosumab: A case series and review of the literature

Giant cell tumor (GCT) of the bone also known as osteoclastoma typically arises from meta-epiphyseal region long and comprises 5% all tumors 20% benign tumors. Understanding pathogenesis is key to successful systemic therapy with denosumab, a RANK-ligand inhibitor. In this context, we report seven GCT bone-treated denosumab radiotherapy cases diverse clinical presentation our institute, NRS Medical College, Hospital Kolkata.